Antimicrobial Agents and Chemotherapy

Biography

Biography: Fenglei Wu

Abstract

Objective: To evaluate the association between a single nucleotide polymorphism (SNP) in human Equilibrative Nucleoside Transporter 1 (hENT1) and the therapeutic efficacy of gemcitabine-containing chemotherapy as well as the prognosis ofthe patients with Non-Small Cell Lung Cancer (NSCLC). Methods: Two hundred and twenty five patients with Stage III (A+B) or IV NSCLC who received gemcitabine-containing chemotherapy was recruited and genotyped for hENT1G-706C (rs61758845) using PCR–restriction fragment length polymorphism assays (RFLP). The association between hENT1G-706C and therapeutic efficacy of gemcitabine-containing chemotherapy was statistically evaluated. Results: Both genotype and allele frequency of hENT1G-706C polymorphism differed significantly between responders and poor-responders. To be more specific, the response rate in the patients carrying GG genotype was substantially higher than that in the patients with GC or CC genotype. Using logistic regression analysis, we found that GC or CC genotype presented higher risk of being poor-responders compared with the GG genotype (OR=2.34, 95% CI: 1.14–4.80; P=0.02). The overall survival in patients with GG genotype were significantly higher than those with GC or CC genotype (19.0 vs. 15.1 months, P<0.001). The hazard ratio for (GC+CC) genotype was 1.89 (95% CI: 1.23–2.90, compared with GG carriers, P=0.004). Conclusions: Our data revealed that hENT1G-706C polymorphism was significantly associated with the therapeutic efficacy of gemcitabine-containing chemotherapy as well as the prognosis in the patients with NSCLC, and it may represent a novel biomarker for the individualization of the treatment of NSCLC.